Is it Time to Dump Illumina, Inc. (ILMN) Stock After it Has Gained 0.80% in a Week?

The market has been neutral on Illumina, Inc. (ILMN) stock recently. ILMN gets a Neutral score from InvestorsObserver Stock Sentiment Indicator.

Illumina, Inc. has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on ILMN!

See Full ILMN Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With ILMN Stock Today?

Illumina, Inc. (ILMN) stock is trading at $95.07 as of 3:33 PM on Monday, Nov 27, a decline of -$3.27, or -3.33% from the previous closing price of $98.34. The stock has traded between $94.91 and $97.80 so far today. Volume today is less active than usual. So far 1,802,686 shares have traded compared to average volume of 2,859,995 shares. To see InvestorsObserver's Sentiment Score for Illumina, Inc. click here.

More About Illumina, Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Click Here to get the full Stock Report for Illumina, Inc. stock.